Lower Survival and Increased Circulating Suppressor Cells in PubMed
The search of prognostic factors is a priority in diffuse large B cell lymphoma DLBCL due to its aggressiveness We have recently found that the level of circulating MDSCs is a good marker of survival in a translational study based on a trial EudraCT Number 2024 001620 29 using lenalidomide combined with R GDP rituximab plus gemcitabine cisplatin and dexamethasone